The European Medicines Agency (EMA) announced it will review the risk of a life threatening metabolic condition known as ketoacidosis from the use of certain type 2 diabetes drugs known as SGLT2 inhibitors. The review comes just after the U.S. Food and Drug Administration (FDA) ordered that warnings be placed on the labels of SGLT2 drugs advising patients and doctors of this risk. Ketoacidosis is a serious diabetes complication where the body produces excess blood acids, or ketones. It can lead to diabetic coma or death. It generally occurs when insulin levels are too low or during prolonged fasting. However, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.